Which score best predicts new-onset AF after primary PCI in STEMI? Head-to-head assessment of four algorithms
- 1Department of Cardiology, Shaoxing Central Hospital
Abstract
Background: New-onset atrial fibrillation (NOAF) is a frequent and clinically significant comorbidity following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), associated with increased mortality, stroke risk, and healthcare costs. Predicting NOAF in this setting remains challenging. This study aimed to compare the predictive performance of four risk scores—CHA ₂ DS ₂ -VASc-60, mC2HEST, Mayo-AF, and HATCH—in identifying patients at high risk of NOAF after primary PCI in STEMI.
Methods: We conducted a single-center, retrospective cohort study at Shaoxing Central Hospital, including consecutive adults with STEMI who underwent primary PCI within 12 h of symptom onset between February 2020 and June 2025. Patients with a history of atrial fibrillation or other exclusions were excluded. The endpoint was NOAF within 1 year after PCI, documented by continuous inpatient telemetry, 12-lead ECG at discharge, and routine follow-up ECGs at 1, 3, 6, 9 and 12 months. We compared the discriminative ability of the four scores using receiver operating characteristic (ROC) curves and assessed their clinical utility through net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
Results: A total of 1,175 patients were included in the final analysis. The incidence of NOAF within 1 year was 8.2% ( n = 96). The mC2HEST score demonstrated the highest area under the ROC curve (AUC) for predicting NOAF (AUC = 0.786), followed by HATCH (AUC = 0.746) and CHA ₂ DS ₂ -VASc-60 (AUC = 0.739), while Mayo-AF had the lowest AUC (AUC = 0.736).
Pairwise comparisons showed that mC2HEST significantly outperformed CHA ₂ DS ₂ -VASc-60 ( Δ AUC = 0.046, p = 0.002).
Conclusions: Among the four risk scores evaluated, mC2HEST provided the best predictive performance for NOAF after primary PCI in STEMI patients. Its superior discriminative ability and significant integrated discrimination improvement suggest that mC2HEST could be a valuable tool for identifying high-risk patients who may benefit from intensified monitoring and early interventions. Future prospective, multicenter studies are warranted to validate these findings.
Related
- Prevalence and Clinical Correlates of Coronary Perivascular Inflammation in an Asymptomatic Adult Primary Prevention Population: An Assessment of the CT-Derived Fat Attenuation Index Score (FAI-Score)
- A biomarker risk score predicts adverse cardiovascular outcomes in patients with angina and non-obstructive coronary artery disease
- A single-cell derived immune risk score predicts recurrence in NSCLC following neoadjuvant chemo-immunotherapy
- A data-driven regional amyloid PET score predicts cognitive decline beyond Centiloid
- A Simple Clinical Score Using Hemoglobin, Age, and BMI Effectively Predicts Possible Sarcopenia
BibTeX
@article{zhou2026which,
title = {{Which score best predicts new-onset AF after primary PCI in STEMI? Head-to-head assessment of four algorithms}},
author = {Xiaofeng Zhou and Hailiang Ma and Zhenhua Jiang},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1835662},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1835662/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Which score best predicts new-onset AF after primary PCI in STEMI? Head-to-head assessment of four algorithms
AU - Xiaofeng Zhou
AU - Hailiang Ma
AU - Zhenhua Jiang
PY - 2026
DA - 2026/10/21
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1835662
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1835662/full
AB - Background: New-onset atrial fibrillation (NOAF) is a frequent and clinically significant comorbidity following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), associated with increased mortality, stroke risk, and healthcare costs. Predicting NOAF in this setting remains challenging. This study aimed to compare the predictive performance of four risk scores—CHA ₂ DS ₂ -VASc-60, mC2HEST, Mayo-AF, and HATCH—in identifying patients at high risk of NOAF after primary PCI in STEMI. Methods: We conducted a single-center, retrospective cohort study at Shaoxing Central Hospital, including consecutive adults with STEMI who underwent primary PCI within 12 h of symptom onset between February 2020 and June 2025. Patients with a history of atrial fibrillation or other exclusions were excluded. The endpoint was NOAF within 1 year after PCI, documented by continuous inpatient telemetry, 12-lead ECG at discharge, and routine follow-up ECGs at 1, 3, 6, 9 and 12 months. We compared the discriminative ability of the four scores using receiver operating characteristic (ROC) curves and assessed their clinical utility through net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: A total of 1,175 patients were included in the final analysis. The incidence of NOAF within 1 year was 8.2% ( n = 96). The mC2HEST score demonstrated the highest area under the ROC curve (AUC) for predicting NOAF (AUC = 0.786), followed by HATCH (AUC = 0.746) and CHA ₂ DS ₂ -VASc-60 (AUC = 0.739), while Mayo-AF had the lowest AUC (AUC = 0.736). Pairwise comparisons showed that mC2HEST significantly outperformed CHA ₂ DS ₂ -VASc-60 ( Δ AUC = 0.046, p = 0.002). Conclusions: Among the four risk scores evaluated, mC2HEST provided the best predictive performance for NOAF after primary PCI in STEMI patients. Its superior discriminative ability and significant integrated discrimination improvement suggest that mC2HEST could be a valuable tool for identifying high-risk patients who may benefit from intensified monitoring and early interventions. Future prospective, multicenter studies are warranted to validate these findings.
SN - 2297-055X
ER -